Momelotinib
- Generic Name
- Momelotinib
- Brand Names
- Ojjaara, Omjjara
- Drug Type
- Small Molecule
- Chemical Formula
- C23H22N6O2
- CAS Number
- 1056634-68-4
- Unique Ingredient Identifier
- 6O01GMS00P
- Background
Momelotinib is a Janus Kinase 1 (JAK1) and 2 (JAK2) inhibitor. It is a competitive inhibitor of JAK ATP binding. First approved by the FDA on September 15, 2023, momelotinib is used to treat myelofibrosis. Myelofibrosis (MF) is a group of myeloproliferative neoplasms characterized by abnormal proliferative hematopoietic stem cells, leading to the release of ...
- Indication
Momelotinib is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [postpolycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia.
- Associated Conditions
- High risk Myelofibrosis, Intermediate risk Myelofibrosis
- Associated Therapies
- -
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 56
- Registration Number
- NCT06517875
A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-12-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06235801
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
- Conditions
- Interventions
- First Posted Date
- 2023-08-08
- Last Posted Date
- 2024-07-24
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 118
- Registration Number
- NCT05980806
- Locations
- 🇺🇸
Duke University, Durham, North Carolina, United States
🇺🇸Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇧🇪UZ Gent, Gent, Belgium
Managed Access Program for Momelotinib in Myelofibrosis
- Conditions
- First Posted Date
- 2022-10-17
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT05582083
A Study of Oral TP-3654 in Patients With Myelofibrosis
- Conditions
- Interventions
- First Posted Date
- 2019-11-25
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT04176198
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Montefiore Cancer Center, Bronx, New York, United States
A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM)
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 195
- Registration Number
- NCT04173494
- Locations
- 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇨🇦Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 87
- Registration Number
- NCT02124746
Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF
- First Posted Date
- 2014-04-02
- Last Posted Date
- 2023-05-23
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 156
- Registration Number
- NCT02101268
Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2014-04-01
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 25
- Registration Number
- NCT02101021
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- Sierra Oncology LLC - a GSK company
- Target Recruit Count
- 39
- Registration Number
- NCT01998828
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.